RetinalGeniX Technologies Inc (RTGN): The outcome of the clinical trials is in...

Reply Private New

Next 10 Prev Next

Send PM Follow Ignore

Re: None

Saturday, 04/25/2015 8:40:19 AM

Saturday, April 25, 2015 8:40:19 AM

The outcome of the clinical trials is interesting because of the high rate of infection associated with abdominal surgery.

Keep Last Read

Next 10 Prev Next

Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/19/2024 01:44:11 PM
Form NT 10-Q - Notification of inability to timely file Form 10-Q or 10-QSB • Edgar (US Regulatory) • 08/14/2024 10:12:57 AM
Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 05/20/2024 01:46:09 PM
Form NT 10-Q - Notification of inability to timely file Form 10-Q or 10-QSB • Edgar (US Regulatory) • 05/16/2024 08:05:20 PM
Form EFFECT - Notice of Effectiveness • Edgar (US Regulatory) • 05/13/2024 04:15:37 AM
Form POS AM - Post-Effective amendments for registration statement • Edgar (US Regulatory) • 02/06/2024 10:30:14 PM
Form POS AM - Post-Effective amendments for registration statement • Edgar (US Regulatory) • 12/29/2023 09:49:01 PM
Form POS AM - Post-Effective amendments for registration statement • Edgar (US Regulatory) • 12/29/2023 09:40:14 PM
Form 8-K - Current report • Edgar (US Regulatory) • 12/06/2023 09:05:38 PM
Form 8-K - Current report • Edgar (US Regulatory) • 12/04/2023 02:46:33 PM
Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/14/2023 11:21:27 AM
Form POS AM - Post-Effective amendments for registration statement • Edgar (US Regulatory) • 11/06/2023 07:22:01 PM
Form POS AM - Post-Effective amendments for registration statement • Edgar (US Regulatory) • 11/06/2023 07:21:55 PM

InvestorsHub NewsWire

Only $200 per official company press release!